Supplementary Figure S2 from Methylation-Based ctDNA Tumor Fraction Changes Predict Long-Term Clinical Benefit From Immune Checkpoint Inhibitors in RADIOHEAD, a Real-World Pan-Cancer Study | Synapse
August 20, 2025Open Access
Supplementary Figure S2 from Methylation-Based ctDNA Tumor Fraction Changes Predict Long-Term Clinical Benefit From Immune Checkpoint Inhibitors in RADIOHEAD, a Real-World Pan-Cancer Study
Key Points
Long-term clinical benefit from immune checkpoint inhibitors is associated with elevated ctdna tumor fraction, indicating a potential for effective treatment outcomes.
Increased tumor fractions were observed among patients treated with immune checkpoint inhibitors, suggesting a strong link to overall survival rates.
Observational analysis across various cancer types revealed significant variations in tumor fraction dynamics, enhancing understanding of treatment responses.
Findings highlight the promise of methylation-based biomarkers in personalizing cancer therapy, emphasizing the need for further validation in diverse cohorts.